BenevolentAI annual revenue for the 2018 fiscal year was £6.8 million.
The company claims to be a "global leader in the development and application of artificial intelligence (“AI”) for scientific innovation."
According to an article by Entrepreneur Media, Inc., five trends in the biotechnology industry include "intellectual property and legal growth, commercial model for value-based pricing for biotech products, partnerships and collaborations among new scrutiny, clinical testing and drug regularisations, and flourished innovations and investment opportunities."
The company promises to reduce the time and money spent on the development of new drugs through artificial intelligence. "Instead of trying to discover a new compound from scratch, BenevolentAI uses its AI system to try to find new drug candidates from existing information and new potential uses for existing drug candidates."
BenevolentAI host an annual award for medical research charities. Winners of the charity award are aided in their medical research towards potentially developing new treatments and therapies through artificial intelligence.
Only the project owner can select the next research path.